表紙
市場調查報告書

生物相似藥單株抗體(mAbs)的全球市場:2020年∼2024年

Global Biosimilar monoclonal antibodies (mAbs) Market 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 932417
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
生物相似藥單株抗體(mAbs)的全球市場:2020年∼2024年 Global Biosimilar monoclonal antibodies (mAbs) Market 2020-2024
出版日期: 2020年04月10日內容資訊: 英文 120 Pages
簡介

全球生物相似藥單株抗體(mAbs)市場在2020年∼2024年的預測期間內,預計將以30%的年複合成長率增長,達到86億5,000萬美元的規模。市場成長的主要因素有慢性疾病患病率的增加,和重量級mAb的專利到期增加。特別是由於慢性疾病患病率的增加有望進一步促進市場增長。

本報告提供全球生物相似藥單株抗體(mAbs)市場相關調查分析,提供市場規模及成長率,市場趨勢,推動市場要素,課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

摘要整理

市場形勢

市場規模

  • 市場定義
  • 市場區隔分析
  • 2019年的市場規模
  • 市場預測:從2019年到2024年的預測

波特的五力分析

各應用領域市場區隔

  • 市場區隔
  • 各應用領域比較:市場規模·預測(2019年∼2024年)
  • 癌症
  • 非癌症
  • 各應用領域的市場機會

客戶形勢

  • 概要

各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模·預測(2019年∼2024年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 各地區的市場機會

成長要素,課題,及趨勢

  • 市場成長要素
  • 交易量的成長要素-需求主導型成長
  • 交易量的成長要素-供給主導型成長
  • 交易量的成長要素-外部要素
  • 交易量的成長要素-需求轉移到鄰近市場
  • 價格上升要素-通貨膨脹
  • 價格成長要素-從低價格單位轉變到高價格單位
  • 市場課題
  • 市場趨勢

業者情勢

  • 概要
  • 形勢的創新

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • Amgen Inc.
  • BIOCAD
  • Biocon Ltd.
  • BioXpress Therapeutics SA
  • Boehringer Ingelheim International GmbH
  • Celltrion Inc.
  • Coherus BioSciences Inc.
  • Intas Pharmaceuticals Ltd.
  • Novartis AG
  • Pfizer Inc.

附錄

目錄
Product Code: IRTNTR41616

Technavio has been monitoring the biosimilar monoclonal antibodies (mAbs) market and it is poised to grow by $ 8.65 bn during 2020-2024 progressing at a CAGR of 30% during the forecast period. Our reports on biosimilar monoclonal antibodies (mAbs) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increase in prevalence of chronic diseases and increase in the number of expiring patents of blockbuster mAbs. In addition, the increase in prevalence of chronic diseases is anticipated to boost the growth of the market as well.

The biosimilar monoclonal antibodies (mAbs) market analysis include applications segments and geographical landscapes

Technavio's ‘ biosimilar monoclonal antibodies (mAbs) market ’ is segmented as below:

By Application

  • Cancer
  • Non-cancer

By Geograohic Landscapes

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the growing approval for biosimilar mAbs as one of the prime reasons driving the biosimilar monoclonal antibodies (mAbs) market growth during the next few years.

"Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our biosimilar monoclonal antibodies (mAbs) market covers the following areas:

  • Biosimilar monoclonal antibodies (mAbs) market sizing
  • Biosimilar monoclonal antibodies (mAbs) market forecast
  • Biosimilar monoclonal antibodies (mAbs) market industry analysis"

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading biosimilar monoclonal antibodies (mAbs) market vendors that include Amgen Inc., BIOCAD, Biocon Ltd., BioXpress Therapeutics SA, Boehringer Ingelheim International GmbH, Celltrion Inc., Coherus BioSciences Inc., Intas Pharmaceuticals Ltd., Novartis AG, and Pfizer Inc.. Also, the biosimilar monoclonal antibodies (mAbs) market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Application

  • Market segments
  • Comparison by Application placement
  • Cancer - Market size and forecast 2019-2024
  • Non-cancer - Market size and forecast 2019-2024
  • Market opportunity by Application

Customer landscape

  • Overview

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography

Drivers, Challenges, and Trends

  • Market drivers
  • Volume driver - Demand led growth
  • Volume driver - Supply led growth
  • Volume driver - External factors
  • Volume driver - Demand shift in adjacent markets
  • Price driver - Inflation
  • Price driver - Shift from lower to higher priced units
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Amgen Inc.
  • BIOCAD
  • Biocon Ltd.
  • BioXpress Therapeutics SA
  • Boehringer Ingelheim International GmbH
  • Celltrion Inc.
  • Coherus BioSciences Inc.
  • Intas Pharmaceuticals Ltd.
  • Novartis AG
  • Pfizer Inc.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibits

  • 1.Key Finding 1
  • 2.Key Finding 2
  • 3.Key Finding 3
  • 4.Key Finding 5
  • 5.Key Finding 6
  • 6.Key Finding 7
  • 7.Key Finding 8
  • 8.Market in focus
  • 9.Parent market
  • 10.Market characteristics
  • 11.Product / Service portfolio of key vendors included in the market definition
  • 12.Market segments
  • 13.Global - Market size and forecast 2019 - 2024 ($ billion)
  • 14.Global market: Year-over-year growth 2019 - 2024 (%)
  • 15.Five forces analysis 2019 & 2024
  • 16.Bargaining power of buyers
  • 17.Bargaining power of suppliers
  • 18.Threat of new entrants
  • 19.Threat of substitutes
  • 20.Threat of rivalry
  • 21.Market condition - Five forces 2019
  • 22.Application placement - Market share 2019-2024 (%)
  • 23.Comparison by Application placement
  • 24.Cancer - Market size and forecast 2019-2024 ($ billion)
  • 25.Cancer - Year-over-year growth 2019-2024 (%)
  • 26.Non-cancer - Market size and forecast 2019-2024 ($ billion)
  • 27.Non-cancer - Year-over-year growth 2019-2024 (%)
  • 28. Market opportunity by Application
  • 29.Customer landscape
  • 30.Market share by geography 2019-2024 (%)
  • 31.Geographic comparison
  • 32.North America - Market size and forecast 2019-2024 ($ billion)
  • 33.North America - Year-over-year growth 2019-2024 (%)
  • 34.Europe - Market size and forecast 2019-2024 ($ billion)
  • 35.Europe - Year-over-year growth 2019-2024 (%)
  • 36.Asia - Market size and forecast 2019-2024 ($ billion)
  • 37.Asia - Year-over-year growth 2019-2024 (%)
  • 38.ROW - Market size and forecast 2019-2024 ($ billion)
  • 39.ROW - Year-over-year growth 2019-2024 (%)
  • 40.Key leading countries
  • 41.Market opportunity by geography ($ billion)
  • 42.Impact of drivers and challenges
  • 43.Vendor landscape
  • 44.Landscape disruption
  • 45.Industry risks
  • 46.Vendors covered
  • 47.Market positioning of vendors
  • 48.Amgen Inc. - Overview
  • 49.Amgen Inc. - Business segments
  • 50.Amgen Inc. - Key offerings
  • 51.Amgen Inc. - Key customers
  • 52.Amgen Inc. - Segment focus
  • 53.BIOCAD - Overview
  • 54.BIOCAD - Product and service
  • 55.BIOCAD - Key offerings
  • 56.BIOCAD - Key customers
  • 57.BIOCAD - Segment focus
  • 58.Biocon Ltd. - Overview
  • 59.Biocon Ltd. - Business segments
  • 60.Biocon Ltd. - Key offerings
  • 61.Biocon Ltd. - Key customers
  • 62.Biocon Ltd. - Segment focus
  • 63.BioXpress Therapeutics SA - Overview
  • 64.BioXpress Therapeutics SA - Business segments
  • 65.BioXpress Therapeutics SA - Key offerings
  • 66.BioXpress Therapeutics SA - Key customers
  • 67.BioXpress Therapeutics SA - Segment focus
  • 68.Boehringer Ingelheim International GmbH - Overview
  • 69.Boehringer Ingelheim International GmbH - Business segments
  • 70.Boehringer Ingelheim International GmbH - Key offerings
  • 71.Boehringer Ingelheim International GmbH - Key customers
  • 72.Boehringer Ingelheim International GmbH - Segment focus
  • 73.Celltrion Inc. - Overview
  • 74.Celltrion Inc. - Business segments
  • 75.Celltrion Inc. - Key offerings
  • 76.Celltrion Inc. - Key customers
  • 77.Celltrion Inc. - Segment focus
  • 78.Coherus BioSciences Inc. - Overview
  • 79.Coherus BioSciences Inc. - Business segments
  • 80.Coherus BioSciences Inc. - Key offerings
  • 81.Coherus BioSciences Inc. - Key customers
  • 82.Coherus BioSciences Inc. - Segment focus
  • 83.Intas Pharmaceuticals Ltd. - Overview
  • 84.Intas Pharmaceuticals Ltd. - Business segments
  • 85.Intas Pharmaceuticals Ltd. - Key offerings
  • 86.Intas Pharmaceuticals Ltd. - Key customers
  • 87.Intas Pharmaceuticals Ltd. - Segment focus
  • 88.Novartis AG - Overview
  • 89.Novartis AG - Business segments
  • 90.Novartis AG - Key offerings
  • 91.Novartis AG - Key customers
  • 92.Novartis AG - Segment focus
  • 93.Pfizer Inc. - Overview
  • 94.Pfizer Inc. - Business segments
  • 95.Pfizer Inc. - Key offerings
  • 96.Pfizer Inc. - Key customers
  • 97.Pfizer Inc. - Segment focus
  • 98.Currency conversion rates for US$
  • 99.Research Methodology
  • 100.Validation techniques employed for market sizing
  • 101.Information sources
  • 102.List of abbreviations